SCHEMBL5196849

SCHEMBL5196849

CCn1c(-c2c(C)cccc2Cl)nc(-c2ccncc2)c1-c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 1/20 0.40
MAPK14 Q16539 5/20 0.38
MAPK11 Q15759 4/20 0.38
MAPK13 O15264 3/20 0.38
MAPK12 P53778 3/20 0.38
PDE2A O00408 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FABP4 P15090 2/20 0.35
PSD A5PKW4 1/20 0.35
FABP5 Q01469 1/20 0.35
OPRL1 P41146 1/20 0.35
GCGR P47871 2/20 0.34
RAF1 P04049 1/20 0.34
IDO1 P14902 2/20 0.34
SRC P12931 1/20 0.34
BRAF P15056 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5194034 0.94 TEK (0.42) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5198874 0.94 TEK (0.42) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5199957 0.89 MAPK14 (0.49) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5197130 0.87 TEK (0.42) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5197719 0.85 MAPK14 (0.48) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5200226 0.84 FABP4 (0.43) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5197084 0.84 TEK (0.46) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5198855 0.84 TEK (0.44) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5198712 0.82 TEK (0.48) TEKMAPK14MAPK11MAPK13MAPK12
SCHEMBL5196505 0.81 MAPK14 (0.40) TEKMAPK14KDM4EFABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101155796-A Imidazole derivatives HOFFMANN LA ROCHE (CH) 2008-04-02 CN claimed
EP-1846389-A1 IMIDAZOLE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-10-24 EP claimed
WO-2006082002-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-08-10 WO claimed
US-20060173048-A1 Imidazole derivatives F. HOFFMAN-LA ROCHE AG (CH) 2006-08-03 US claimed
CN-101155796-A Imidazole derivatives HOFFMANN LA ROCHE (CH) 2008-04-02 CN disclosed
US-20060173048-A1 Imidazole derivatives F. HOFFMAN-LA ROCHE AG (CH) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173048-A1 Imidazole derivatives GRM2, GRM1, GRIN2C TEK 3703/4885MAPK14 2620/4885MAPK11 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.